Following the news that the UK has succeeded in eliminating measles, Dr Emma St Clair Pearce, the ABPI’s newly appointed Research and Collaboration Policy Officer, writes that while the UK’s success of limiting the spread of the virus through vaccination should be heralded, national figures for MMR vaccine uptake show we should still prioritise maintaining and improving coverage.
Join the ABPI and AMRC to explore a wealth of case studies highlighting the many benefits in establishing, managing and growing partnerships that aim to benefit patients sooner.
27 Jul 2017
Following the publication of ‘Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study’, the Association of the British Pharmaceutical Industry has issued the following statement.
26 Jul 2017
Dr Sheuli Porkess, ABPI's Head of Medical Affairs, says:
18 Jul 2017
A new report published today shows that the UK is trailing behind the rest of Europe in the treatment of cancer. British patients have worse survival rates after five years - the international benchmark for measuring the quality of cancer care – compared to the European average in nine out of ten cancers – only exceeding the EU average in melanoma.
14 Jul 2017
The Association of the British Pharmaceutical Industry (ABPI) have responded to an announcement made today by Health Minister Lord O’Shaughnessy to spend £86 million "to help develop real world medical breakthroughs that will help patients across the NHS."
06 Jul 2017
The Department of Health has today [6 July] published the Q1 2017 PPRS data showing that the pharmaceutical industry has paid £94 million during the first quarter (Q1) of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).
20 Jan 2017
The Declaration on Combating Antimicrobial Resistance (AMR) represents a major milestone in the global response to the rising threat of drug resistance with commercial drug and diagnostic developers for the first time agreeing on a common set of principles. One year on, the IFMPA sets out 7 key principles to incentivize the development of new antibiotics & vaccines.